UNSPSC 51453008: Piperazine dihydrochloride

This classification denotes an antihelminthic agent with the molecular formula C4H10N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17VU4Z4W88, chemically known as piperazine, dihydrochloride but more generally known as piperazine dihydrochloride, which bears US NIH Compound Identifier 8893. European Medicines Agency schedules Piperazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14887MIG.

Most nations, for tariff and trade purposes, schedule piperazine dihydrochloride under HS 29335990. As of Q4 2014, PIPERAZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Piperazine dihydrochloride bears US NLM identifiers UMLS ID C0892283 and NCI Concept Code C80008. SMILES: C1CNCCN1.CL.CL.

UNSPSC 51453008 Piperazine dihydrochloride is a Commodity code representing specialized pharmaceutical chemical products, though recent state and local solicitations under this code show minimal direct alignment with the abstract product name. The code sees activity from health departments and municipal first-responder agencies procuring pharmaceutical supplies and over-the-counter medical products for emergency response and public health initiatives. State and local governments buying under this code are typically county health departments, city fire departments, and multi-state cooperative purchasing alliances that aggregate demand across member agencies. Seminole County, Florida and the City of Tampa have recently posted solicitations for naloxone, deactivation systems, and emergency medical supplies; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has solicited generic pharmaceuticals and OTC products for distribution across participating state and local facilities. The Texas Health and Human Services Commission has issued an RFI exploring direct-to-manufacturer prescription programs, signaling state-level interest in restructuring pharmacy benefit procurement channels.

Recent activity concentrates in Florida and the upper Midwest, with multi-state cooperative purchasing agreements extending reach to Oregon and other participating jurisdictions. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26-P-00145 (posted March 25, 2026; due March 13, 2026) for 169 line items of medical and first aid supplies with an estimated contract value of $700,000 and a 5 percent small local business enterprise bid discount; and MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with contract effectiveness July 1, 2026. The Tampa procurement is sheltered for certified Small Local Business Enterprises. MMCAP's evaluation weights price competitiveness at 75 percent, with fixed pricing, compliance with administrative format requirements, EDI capability, and agreement to a 3 percent administrative fee each scoring 5–10 percent. The Texas RFI remains a preliminary information-gathering mechanism with no formal evaluation criteria or award timeline specified at this stage.